Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
September 24, 2021
Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc.
September 22, 2021
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members
September 20, 2021
Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes
September 8, 2021
Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
June 21, 2021
Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant
June 14, 2021
Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting
June 1, 2021
Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease
May 26, 2021
Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
May 19, 2021
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation
May 6, 2021
Displaying 1 - 10 of 14